Why the study?
Does transcatheter aortic valve implantation (TAVI) provide a safe and effective treatment for high-risk patients with a failing surgical aortic bioprosthesis?
Population
18 patients ≥ 75 years old with a failing surgical aortic bioprosthesis and high surgical risk. Mean age 79…
Design
Case_series
Follow-up
1 year
Key result
Transcatheter aortic valve implantation in a failing surgical aortic bioprosthesis was technically successful in 94% of cases, with 30-day and 1-year mortality rates of 11% and 28%, respectively.
Authors
Loading...
Supports valve-in-valve TAVI feasibility in high-risk cases; leaves open durability, safety, and comparative outcomes.
Observational (n=18)
Yes
Does transcatheter aortic valve implantation (TAVI) provide a safe and effective treatment for high-risk patients with a failing surgical aortic bioprosthesis?
TAVI is a technically feasible and effective valve-in-valve treatment option for high-risk patients with failing surgical aortic bioprostheses, demonstrating acceptable short- and mid-term outcomes.
Ong et al. (2012) conducted an observational in Failing surgical aortic bioprosthesis (n=18). Transcatheter aortic valve implantation (TAVI) with 18-Fr CoreValve was evaluated on Technical success. Transcatheter aortic valve implantation in a failing surgical aortic bioprosthesis was technically successful in 94% of cases, with 30-day and 1-year mortality rates of 11% and 28%, respectively.